Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/1997

01-05-1997

Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer

Authors: James N. Ingle, Carl G. Kardinal, Vera J. Suman, Michael H. Veeder, Paul L. Schaefer, Ronnie J. Kirschling, James A. Mailliard

Published in: Breast Cancer Research and Treatment | Issue 3/1997

Login to get access
Metadata
Title
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer
Authors
James N. Ingle
Carl G. Kardinal
Vera J. Suman
Michael H. Veeder
Paul L. Schaefer
Ronnie J. Kirschling
James A. Mailliard
Publication date
01-05-1997
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/1997
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1005749115033

Other articles of this Issue 3/1997

Breast Cancer Research and Treatment 3/1997 Go to the issue

OriginalPaper

Hospital-related differences in breast cancer management

OriginalPaper

Establishment and characterisation of new cell lines from human breast tumours initially established as tumour xenografts in NMRI nude mice

OriginalPaper

Guidelines for systemic therapy of early stage breast cancer

OriginalPaper

Feasibility of obtaining breast epithelial cells from healthy women for studies of cellular proliferation

OriginalPaper

Prognostic significance of etiological risk factors in early breast cancer

OriginalPaper

Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits